(MM) (DNDN) Share Price

How did that work out for you?

Dew, Thanks, my friends are not in the US but I will certainly follow up on the link you provided.

I am wondering in you have read the book on what happened with DNDN:

https://www.amazon.com/Dendreon-Effect-men-Manipulate-High-tech/dp/1563431416

Not sure what I think though I do remember that at the time thinling that the system had been somewhat compromised to the detriment of cancer patients.

Hi. There are several approved drugs approved for prostate cancer that were not available when Provenge was launched about ten years ago. Before making a treatment decision, any cancer patient should consider getting a genetic screen such as FoundationOne CDx (https://www.foundationmedicine.com/genomic-testing/foundation-one-cdx ), which is offered by Foundation Medicine, a subsidiary of Roche.

Good luck. Regards, Dew

I an doing some research into Dendrion for two reasons

1. Cloee friends have Prostate Cancer
2 Dendreon effect has been brought up

I remember you were involved in posting on the Advisory meeting and other DNDN events. We both posted on GENR board.

Wonder if you are still around and have any comments in hindsight.

No volume, no revenue, no information, debt issues everyone has moved on.

A

DNDN from LONG AGO... since someone posted it on another board

Posted on 18 June 2009

https://www.deepcapture.com/2009/06/michael-milken-60000-deaths-and-the-story-of-dendreon-chapter-1-of-15/

Don't think so...

one of the worst collapses in stock market history,4 years of misery

It is still $45 if you take in account all the outstanding shares. If the market cap goes down by half while at the same time share value has doubled from .01 to .02 then what has taken place for this to happen.


You have a +100% move upwards and a 50% move downwards your aand the last known outstanding share count was 60 million.


The spread is a 150% times 60 million equals 180 million shares from 60 million she is not rocket science how it is done my friends. Remember you can't sell nothing and what you do have you can ask the world should someone agree to pay the price for it.



Now take the asset value and divide that by the new outstanding shares and is not the value reflective of the price when taking in the debt owed to previous share holders.


Everyone pays the same price if you don't trade while others pay less or more in some cases who do trade the stock.

Link to bankruptcy information:

https://cases.primeclerk.com/dendreon/

The final nail, from today at Fidelity:
06/12/2015 EXPIRED DENDREON CORP COM **EXPIRED POSITION**
24823Q107 DENDREON CORP COM **EXPIRED POSITION**

I'm waiting for it to reach par status before buying to avoid dilution.

Chapter 11 is money owed to owners where as chapter 7 is to creditors like banks ect. The collateral is in threat not that investors have to come up with more capital but it does help some when they do sell them at par to raise more capital.

Waiting for the dust to settle....all Q can't be all winners that's why the Q stands for Questionable ;/ maybe a small light at end of the tunnel?

Bankruptcy Plan Effective/Shares Cancelled 06/11/2015

http://otce.finra.org/DailyList

we may see it at .45 very soon!

This was once 45.00 a share lmao at this disaster

Going long and strong.....high risk high reward....that's the name of this game ;)

DNDNQ to open over a dime on Monday!

Will see what happens on the 9th :)

Going long and strong last shake out for weak hands...we will see on the 10th the outcome.....high risk high reward....the name of this game ;)

Read doc 738 ;)

Going long and strong unsecured holders will receive lollipops :)~~~~~

docket 714 is interesting, what do you think about it?

Wake wake it's almost June or maybe July will see if we get our lollipop ;) holding long and strong

http://www.fasb.org/jsp/FASB/Document_C/DocumentPage?cid=1218220130001&acceptedDisclaimer=true

Looks good on paper. Moved on guys see you at the next play.

They don,t tell you stuff like that. If you should ask they will deny your conspiracy but again it is true that if you buy land dig a whole and add cement you have devalued that land until the completion of the final product and should that product be ten years older down the block and be of the same DNA it will be priced at the last sale on the block.


Now if it is full of special equipment designed for a particular process well then it is priced at what it produces in profits.



So as you see it can all be manipulated and what one has to do is make the ones in charge accountable.

Anyhow the long and short is I don't know so I won't hang on to them cause I don't know and what I have is only speculation on my part and my buddies who I share the alias with.

Hmmmmmmm let me know when you find out :)

What year?

Patient wake me up in June :)

Still holding no bids and no asks? She is in limbo.

This is to funny.

http://www.deonsupply.com/


Fighting cancer by taking the recycled oil process out of the equation.

http://en.wikipedia.org/wiki/Automotive_oil_recycling


Did you now that the industry encourages you to change your oil more often due too the refining process along with always changing your oil filter on a regular bases to cut down refining cost.

http://medicinehatnews.com/alberta-election/stories-features/2015/04/15/independent-candidate-enters-medicine-hat-race/


Good luck Guy.

Not my first rodeo :)

http://www.financialstabilityboard.org/multimedia/fsb-chairs-opening-remarks-at-a-press-briefing-in-basel-ahead-of-the-g20-summit-in-brisbane/

http://www.financialstabilityboard.org/2011/01/cos_051201/

http://www.financialstabilityboard.org/about/fsb-members/



I would read this first.

Apr 13, 2015 13:54:00 (ET)


By Joseph Checkler

Drug maker Dendreon Corp. (DNDNQ) is offering details of how it will distribute to creditors the money from its sale to Valeant Pharmaceuticals International Inc. (VRX, VRX.T).

In a Friday Filing with U.S. Bankruptcy Court in Wilmington, Del., Dendreon said the holders of its key unsecured notes will get between 72 cents and 75 cents on the dollar, thanks to the $495 million sale to Valeant.

Those creditors, the largest group owed money in Dendreon's bankruptcy case, would have gotten much less earlier in the case, but the Valeant offer kept getting higher. At one point, Valeant was only going to buy Dendreon's flagship prostate cancer drug, Provenge, but eventually it bought all the company's assets.

The Friday filing was an updated version of Dendreon's so-called disclosure statement, a plain-language version of a company's restructuring plan on which creditors must vote. A prior version of the document hadn't placed a printed figure on how much the creditors would get. Other unsecured creditors will also get between 72 cents and 75 cents on the dollar.

Originally, Valeant offered $296 million for Dendreon assets, including Provenge. That offer was increased to $400 million when Valeant was approved to serve as the stalking horse, or lead bidder, at a bankruptcy auction that was ultimately canceled when no rival bidders emerged to challenge Valeant. It eventually went up to $495 million.

The deal is Valeant's first big move since its failed hostile takeover of Botox maker Allergan Inc. (AGN). Actavis PLC ended up buying Allergan in November for $66 billion. After losing out on Allergan, Valeant indicated it would focus on expanding its own business. But Dendreon became too tempting a target.

Once a darling of hedge funds betting both on and against Provenge's prospects, Dendreon's market capitalization once topped $7.5 billion after Food & Drug Administration approval of the drug.

But at an average of $93,000 for a course of treatment that improved median survival by just over four months, Provenge wasn't adopted readily by doctors. The company's stock started to plummet in August 2011 after it offered lower revenue guidance, prompting an investor lawsuit, which was eventually settled, and a stock freefall.

That led to a Chapter 11 filing, in November 2014.

Provenge had about $300 million in 2014 revenue. Valeant hired Dendreon's employees and agreed to take over the supply contracts for the acquired business, a component of the purchase that stabilizes Dendreon's operations.

(Dow Jones Daily Bankruptcy Review covers news about distressed companies and those under bankruptcy protection. Go to http://dbr.dowjones.com)

Write to Joseph Checkler at joseph.checkler@wsj.com


Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

April 13, 2015 13:54 ET (17:54 GMT)

Taking her to the bank today.

ready to take off?

Looks like those bag holders will be receiving around .72c to .75c good thing I'm long and strong on this I'll be smiling all the way to the bank :)~~~ more lollipops for me!!!!

Its trading over $.04 down to $.03 how much do you need to be saved. They are doing every thing they can for both the share holders and debt holders by creating depreciated assets for one group and liquidity for another group but it is up too share holders to take advantage of what has been given them.


Debt holders do not get that chance but do get the chance of collecting on the depreciated assets once things are resolved.

why didn't nol's save the shareholders?